BU Clinical HIV/AIDS Research Training Program

描述（由申请人提供）：波士顿大学临床艾滋病毒/艾滋病研究培训（BU-CHART）计划的具体目标是为医生提供严格的研究生培训，使他们能够进行高质量，道德的艾滋病毒/艾滋病研究，重点是弱势群体。BU-CHART将提供与研究药物滥用，医疗保健差异和艾滋病毒感染的并发症相关的研究方法的具体培训。一个特别的重点将是研究伦理方面的正式培训。该计划网站由波士顿大学医学院（BUSM），波士顿大学公共卫生学院（BUSPH）和波士顿医疗中心（BMC）组成，波士顿市的“安全网”医院。BMC是国家成人艾滋病临床试验组（ACTG）、艾滋病预防联盟和CDC赞助的艾滋病毒/结核病合并感染临床试验的一部分。其研究人员在艾滋病毒流行病学、艾滋病毒/丙型肝炎合并感染、艾滋病毒和酗酒、依从性、预防、国际艾滋病毒研究以及艾滋病毒与结核病的相互作用方面的赞助研究方面有着良好的记录。拟议的BU-CHART项目主任Paul Skolnik博士是两个先前的NIAID T32艾滋病毒培训赠款和一个NIAID T32传染病基础研究培训赠款的主要负责人。Skolnik博士有担任成功学员导师的丰富记录，并不断获得与艾滋病毒/艾滋病有关的资金。培训计划执行委员会（EC）将由Horsburgh，Skolnik，Samet，Cotton，Felson博士（他是与此资助合作的K30奖的PI）和中心（最近获得的临床和转化科学奖（CTSA）的PI）组成。在EC的监督下，将通过项目总监与学员的定期会议来监测学员的进度。BU- CHART将在行政上设在BUSM医学系传染病科。每年有两名学员将进入一个结构化的计划，其中包括在BUSPH获得硕士学位，并在项目导师的指导下进行临床研究项目，该项目将构成作为硕士学位一部分提交的论文的基础。学员还将被指派一名道德操守导师，并撰写道德操守论文。每名学员将获指派一名教统会成员作为高级导师。因此，每个受训人员将有一个指导小组。BU-CHART的主要目标是将学员转变为临床研究中的独立医生调查员，他们特别关注弱势群体的研究和研究伦理。 相关性（参见说明）：BU-CHART计划将培训医生通过临床研究回答有关艾滋病毒感染的重要问题，以及如何通过预防和治疗最好地改善人们的健康。BU-CHART将通过与目前进行这些研究的熟练医生的互动，培训下一代艾滋病毒研究人员，以应对未来与男性，女性和儿童艾滋病毒感染有关的挑战。

DESCRIPTION (provided by applicant): The specific aim of the Boston University Clinical HIV/AIDS Research Training (BU-CHART) Program is to provide rigorous postgraduate training to physicians to enable them to conduct high-quality, ethical HIV/AIDS research focused on disadvantaged populations. BU-CHART will provide specific training in research methods of relevance to study substance abuse, healthcare disparities, and co-morbidities of HIV infection. A particular focus will be formal training in research ethics. The Program Site is comprised of the Boston University School of Medicine (BUSM), Boston University School of Public Health (BUSPH), and Boston Medical Center (BMC), the "safety net" hospital for the city of Boston. BMC is part of the national Adult AIDS Clinical Trials Group (ACTG), the AIDS Malignancy Consortium, and CDC-sponsored clinical trials of HIV/tuberculosis co-infection. Its investigators have a strong record of sponsored research in HIV epidemiology, HIV/hepatitis C co-infection, HIV and alcohol abuse, adherence, prevention, international HIV research, and HIV interactions with tuberculosis. The proposed BU-CHART Program Director, Dr. Paul Skolnik, has been the PI of two prior NIAID T32 HIV training grants and an NIAID T32 infectious diseases basic research training grant. Dr. Skolnik has a substantial record of serving as mentor for successful trainees, and has ongoing HIV/AIDS-related funding. The Training Program Executive Committee (EC) will consist of Drs. Horsburgh, Skolnik, Samet, Cotton, Felson (who is PI of a K30 award that is partnered with this grant), and Center (the PI of a recently awarded Clinical and Translational Science Award (CTSA). Trainee progress will be monitored through regular meetings of the Program Director with trainees, with oversight by the EC. BU- CHART will be administratively based in the Section of Infectious Diseases (ID), Department of Medicine, BUSM. Two trainees each year will enter a structured program that includes earning the MSc degree at the BUSPH, and conducting a clinical research project under the guidance of a Project Mentor that will form the basis of a thesis submitted as part of the MSc degree. Trainees will also be assigned an Ethics Mentor and write an ethics paper. A member of the EC will be assigned to each trainee as a Senior Mentor. Thus each trainee will have a mentoring team. The primary goal of BU-CHART, on which all efforts are focused, is to transform trainees into independent, physician-investigators in clinical research who have a special focus on research in disadvantaged populations and research ethics. RELEVANCE (See instructions): The BU-CHART program will train doctors to answer important questions about HIV infection through clinical studies and how best to improve people's health through prevention and treatment. BU-CHART will train the next generation of HIV researchers, through interactions with skilled physicians who currently conduct these studies, to meet the challenges of the future related to HIV infection of men, women, and children.